| The fate of chemoresistance in triple negative breast cancer (TNBC) EA O’Reilly, L Gubbins, S Sharma, R Tully, MHZ Guang, K Weiner-Gorzel, ... BBA clinical 3, 257-275, 2015 | 410 | 2015 |
| Targeting proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis M Ho Zhi Guang, EL Kavanagh, LP Dunne, P Dowling, L Zhang, ... Cancers 11 (1), 66, 2019 | 97 | 2019 |
| Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu L Zhang, YT Tai, M Ho, L Xing, D Chauhan, A Gang, L Qiu, KC Anderson Blood cancer journal 7 (3), e547-e547, 2017 | 84 | 2017 |
| A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity J Liu, T Song, W Zhou, L Xing, S Wang, M Ho, Z Peng, YT Tai, ... Leukemia 33 (1), 171-180, 2019 | 70 | 2019 |
| Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) M Ho, A Patel, CY Goh, M Moscvin, L Zhang, G Bianchi Leukemia 34 (12), 3111-3125, 2020 | 66 | 2020 |
| Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling M Ho, T Chen, J Liu, P Dowling, T Hideshima, L Zhang, E Morelli, ... Leukemia 34 (1), 196-209, 2020 | 60 | 2020 |
| Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses? CY Goh, C Wyse, M Ho, E O'Beirne, J Howard, S Lindsay, P Kelly, ... Cancer letters 473, 90-97, 2020 | 52 | 2020 |
| Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era L Zhang, YT Tai, MZG Ho, L Qiu, KC Anderson Experimental Hematology & Oncology 6, 1-9, 2017 | 37 | 2017 |
| Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’ MHZ Guang, A McCann, G Bianchi, L Zhang, P Dowling, D Bazou, ... Leukemia & lymphoma 59 (3), 542-561, 2018 | 36 | 2018 |
| Role of the bone marrow milieu in multiple myeloma progression and therapeutic resistance M Ho, CY Goh, A Patel, S Staunton, R O’Connor, M Godeau, G Bianchi Clinical Lymphoma Myeloma and Leukemia 20 (10), e752-e768, 2020 | 33 | 2020 |
| The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line TD Chuang, M Ho, O Khorram Reproductive Sciences 22 (5), 563-571, 2015 | 22 | 2015 |
| Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis M Ho, S Zanwar, FK Buadi, S Ailawadhi, J Larsen, L Bergsagel, M Binder, ... American journal of hematology 98 (1), 49-55, 2023 | 21 | 2023 |
| Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival T Chen, M Ho, J Briere, M Moscvin, PG Czarnecki, KC Anderson, ... Blood Advances 6 (2), 429-440, 2022 | 18 | 2022 |
| Exploiting autophagy in multiple myeloma M Ho, A Patel, C Hanley, A Murphy, T McSweeney, L Zhang, A McCann, ... J Cancer Metastasis Treat 5 (70), 1-20, 2019 | 16 | 2019 |
| Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma S Zanwar, M Ho, P Kapoor, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, ... Leukemia 36 (3), 873-876, 2022 | 14 | 2022 |
| Treating multiple myeloma in the context of the bone marrow microenvironment M Ho, A Xiao, D Yi, S Zanwar, G Bianchi Current Oncology 29 (11), 8975-9005, 2022 | 13 | 2022 |
| The effect of duration of lenalidomide maintenance and outcomes of different salvage regimens in patients with multiple myeloma (MM) M Ho, S Zanwar, P Kapoor, M Gertz, M Lacy, A Dispenzieri, S Hayman, ... Blood cancer journal 11 (9), 158, 2021 | 12 | 2021 |
| Primary plasma cell leukemia: Real-world retrospective study of 46 patients from a single-center study in China T Yu, Y Xu, G An, YT Tai, M Ho, Z Li, S Deng, D Zou, Z Yu, M Hao, ... Clinical Lymphoma Myeloma and Leukemia 20 (10), e652-e659, 2020 | 12 | 2020 |
| Carfilzomib inhibits constitutive NF-κB activation in mantle cell lymphoma B cells and leads to the induction of apoptosis YL Zhang, MHZ Guang, HQ Zhuo, XH Min, Q Yao, AQ Gu, SH Wu, ... Acta Haematologica 137 (2), 106-112, 2017 | 12 | 2017 |
| ROBO1 promotes homing, dissemination, and survival of multiple myeloma within the bone marrow microenvironment G Bianchi, PG Czarnecki, M Ho, AM Roccaro, A Sacco, Y Kawano, ... Blood cancer discovery 2 (4), 338-353, 2021 | 11* | 2021 |
